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Abstract
The frog skin host-defense peptide esculentin-2CHa (GFSSIFRGVA10KFASKGLGK
D20LAKLGVDLVA30CKISKQC) displays antimicrobial, antitumor, and immunomodulatory
properties. This study investigated the antidiabetic actions of the peptide and selected ana-
logues. Esculentin-2CHa stimulated insulin secretion from rat BRIN-BD11 clonal pancreatic
β-cells at concentrations greater than 0.3 nM without cytotoxicity by a mechanism involving
membrane depolarization and increase of intracellular Ca2+. Insulinotropic activity was
attenuated by activation of KATP channels, inhibition of voltage-dependent Ca
2+ channels
and chelation of extracellular Ca2+. The [L21K], [L24K], [D20K, D27K] and [C31S,C37S]
analogues were more potent but less effective than esculentin-2CHa whereas the [L28K]
and [C31K] analogues were both more potent and produced a significantly (P < 0.001)
greater maximum response. Acute administration of [L28K]esculentin-2CHa (75 nmol/kg
body weight) to high fat fed mice with obesity and insulin resistance enhanced glucose toler-
ance and insulin secretion. Twice-daily administration of this dose of [L28K]esculentin-
2CHa for 28 days had no significant effect on body weight, food intake, indirect calorimetry
or body composition. However, mice exhibited decreased non-fasting plasma glucose
(P < 0.05), increased non-fasting plasma insulin (P < 0.05) as well as improved glucose tol-
erance and insulin secretion (P < 0.01) following both oral and intraperitoneal glucose
loads. Impaired responses of isolated islets from high fat fed mice to established insulin
secretagogues were restored by [L28K]esculentin-2CHa treatment. Peptide treatment was
accompanied by significantly lower plasma and pancreatic glucagon levels and normaliza-
tion of α-cell mass. Circulating triglyceride concentrations were decreased but plasma cho-
lesterol and LDL concentrations were not significantly affected. The data encourage further
investigation of the potential of esculentin-2CHa related peptides for treatment of patients
with type 2 diabetes.
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Introduction
Skin secretions of many species of Anura (frogs and toads) represent a valuable source of pep-
tides with therapeutic potential. These peptides, whose primary function is believed to be host-
defence, are best known for their antimicrobial properties and there are many examples of
components with potent activity against multidrug-resistant pathogenic Gram-positive and
Gram-negative bacteria and fungi (reviewed in [1–4]). However, frog skin host-defense pep-
tides are multifunctional and may also display anti-tumor, antiviral, immunomodulatory, and
chemoattractive activities (reviewed in [5]). In addition, myotropic peptides produced in the
skin, such as those related to mammalian tachykinins, bradykinin and CCK-8, may play a role
in deterring ingestion by predators [6]. There are no conserved structural domains in amphib-
ian host-defense peptides that are responsible for biological activity but with few exceptions
they are cationic and have the propensity to adopt an amphipathic, α-helical conformation in a
membrane-mimetic solvent or in the environment of a phospholipid vesicle [2].
One such host-defense peptide with therapeutic potential is esculentin-2CHa (GFSSIFRGV
AKFASKGLGKDLAKLGVDLVACKISKQC), first isolated from norepinephrine-stimulated
skin secretions of the Chiricahua leopard frog Lithobates chiricahuensis (Ranidae) [7]. This
compound shows potent broad-spectrum antimicrobial properties including activity against
clinical isolates of multidrug-resistant strains of Staphylococcus aureus, Acinetobacter bauman-
nii, and Stenotrophomonas maltophilia. The peptide also stimulates the release of the anti-
inflammatory cytokine IL-10 by mouse lymphoid cells and displays high cytotoxic potency
against human non-small cell lung adenocarcinoma A549 cells but relatively low hemolytic
activity against human erythrocytes [8]. Interestingly, such actions on cytokine production by
mouse lymphoid cells were also extended to TNF-alpha which may impact on beta cells [8].
Structure-activity studies indicate that removal of the either hydrophobic N-terminal hexapep-
tide (GFSSIF) or the cyclic C-terminal domain (CKISKQC) and replacement of the Cys31 and
Cys37 residues by serine results in appreciable decreases in cytotoxicity against microorganisms
and mammalian cells. In contrast, increasing cationicity by substitution of the Asp20 and Asp27
residues by L-Lysine resulted in a modest increase in potency against all microorganisms tested
(up to 4-fold) [8].
The current pandemic of type 2 diabetes has necessitated a search for new types of therapeu-
tic agents and naturally occurring incretin peptides that stimulate insulin release in response to
high circulating glucose concentration are receiving increasing attention. Several long-acting
analogues of the potent incretin GLP-1 are currently in clinical use [9]. A number of frog skin
peptides that were first identified on the basis of their ability to inhibit the growth of microor-
ganisms have subsequently been shown to possess the ability to release insulin from the
BRIN-BD11 clonal β-cells and isolated mouse islets at low concentrations that are not cytotoxic
to the cells and to improve glucose tolerance in mice following acute administration (reviewed
in [5, 10]). The high fat fed mouse exhibits obesity, glucose intolerance and insulin resistance
and so is a useful model for a preliminary investigation of the therapeutic potential of peptides
in treatment of patients with type 2 diabetes [11]. More recently, it has been shown that twice
daily treatment of high-fat fed mice for up to 28 days with tigerinin-1R [12], magainin-AM1
[13], and CPF-SE1 [14] results in an improvement in glucose tolerance, insulin sensitivity, and
islet β-cell secretory responsiveness.
In the present study, the antidiabetic potential of esculentin-2CHa and selected analogues
with increased cationicity (Table 1) was assessed in vitro using BRIN-BD11 cells and isolated
mouse islets and in vivo in studies using the high fat fed mouse.
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Materials and Methods
Peptide synthesis and purification
Synthetic esculentin-2CHa and its analogues (Table 1) were purchased in crude form GL Bio-
chem Ltd (Shanghai, China) and purified to near homogeneity (> 98% pure) by reversed-
phase HLPC on a (2.2 cm x 25 cm) Vydac 218TP1022 (C18) column equilibrated with acetoni-
trile/water/triflouroacetic acid (21.0/78.9/0.1 v/v) mobile phase at a flow rate of 6 ml/min. The
concentration of acetonitrile in the eluting buffer was raised to 56% (v/v) over 60 min. The
molecular masses of the peptides were confirmed using MALDI-TOF mass spectrometry.
In vitro insulin-releasing studies
In vitro insulin-releasing effects of esculentin-2CHa and its analogues were assessed using
BRIN-BD11 rat clonal β-cells and mouse islets. In the first set of experiments, BRIN-BD11
cells were incubated with the peptides in the concentration range (1 pM– 3 μM) in Krebs-
Ringer bicarbonate buffer containing 5.6 mM glucose for 20 min at 37°C as previously
described [15–17]. Insulin-releasing effects were also assessed using buffer supplemented with
1.4 and 16.7mm glucose concentrations and with established modulators of insulin release as
previously described [15–17]. In a second set of experiments, islets from NIH Swiss mice, iso-
lated by collagenase digestion [18,19], were incubated with a range of concentrations of escu-
lentin-2CHa or its analogues (0.1 nM– 1 μM) for 1 h in Krebs-Ringer bicarbonate (KRB)
buffer supplemented with 1.4, 5.6 or 16.7 mM glucose. Following test incubations, aliquots of
buffer were retrieved and stored at -20°C for measurement of insulin by radioimmunoassay
[20]. In the experiments with BRIN-BD11 cells, the release of lactate dehydrogenase (LDH)
was measured as an indicator of the integrity of the plasma membrane using commercially
available CytoTox 96 non-radioactive cytotoxicity assay kit (Promega, Madison, WI, USA)
according to the manufacturer’s recommended protocol.
Membrane potential studies and intracellular calcium ([Ca2+]i)
Effects of esculentin-2CHa (1 μM) and its analogues on membrane potential and [Ca2+]i in
BRIN-BD11 cells over a period of 5 min were assessed using commercially available FLIPR
membrane or calcium assay kit (Molecular Devices, USA) as previously described [15]. Data
were captured using a Flexstation 3 microplate reader equipped with automatic fluid transfer
unit (Molecular Devices, USA).
Laboratory animals
Male National Institutes of Health (NIH) Swiss mice (Harlan Ltd, UK) were housed separately
in an air-conditioned room (22 ± 2°C) with relative humidity of 51 ± 5% and a 12-hour light:
Table 1. Amino acid sequence and physicochemical properties of esculentin-2CHa and its substituted analogues.
Peptide Sequence Net charge at pH 7 Isoelectric point
Esculentin-2CHa GFSSIFRGVAKFASKGLGKDLAKLGVDLVACKISKQC 5 10.82
[L21K]Esculentin-2CHa GFSSIFRGVAKFASKGLGKDKAKLGVDLVACKISKQC 6 10.91
[L24K]Esculentin-2CHa GFSSIFRGVAKFASKGLGKDLAKKGVDLVACKISKQC 6 10.91
[L28K]Esculentin-2CHa GFSSIFRGVAKFASKGLGKDLAKLGVDKVACKISKQC 6 10.91
[C31K]Esculentin-2CHa GFSSIFRGVAKFASKGLGKDLAKLGVDLVAKKISKQC 6 10.65
[C31S,C37S]Esculentin-2CHa GFSSIFRGVAKFASKGLGKDLAKLGVDLVASKISKQS 5 10.82
[D20K, Lys27]Esculentin-2CHa GFSSIFRGVAKFASKGLGKKLAKLGVKLVACKISKQC 9 11.97
doi:10.1371/journal.pone.0141549.t001
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12-hour dark cycle and maintained on a high fat diet containing 45% fat, 20% protein and 35%
carbohydrate (total energy 19.5 kJ/g, Dietex International Ltd, Witham, UK) for 120 days.
Mice maintained on standard rodent diet containing 10% fat, 30% protein and 60% carbohy-
drates (total energy 12.99 kJ/g) were used as controls. Both groups of animals were allowed
food and water ad libitum. All animal experiments were carried out in accordance with the UK
Animals (Scientific Procedures) Act 1986 and EU Directive 2010/63EU for animal experi-
ments. The study was approved by University of Ulster Research Ethics Committee.
Acute in vivo studies
For acute in vivo studies, overnight fasted, high fat fed mice (n = 8) received an intraperitoneal
injection of glucose alone (18 mmol/kg body weight) or in combination with esculentin-2CHa
or its analogues (75 nmol/kg body weight). This peptide dose was selected on the basis of a
pilot study that examined acute effects of different doses of esculentin-2CHa on glucose
tolerance in lean mice. Blood samples were collected as described previously before injection
and at times indicated in the Figures for the measurement of plasma glucose and insulin
concentrations.
Longer-term in vivo studies
High-fat fed mice with clearly manifested features of obesity and hyperglycaemia received
twice daily injections of either saline vehicle (0.9% (w/v) (high fat fed controls) or [L28K]escu-
lentin-2CHa (75 nmol/kg body weight) for 28 days. This peptide was chosen based on its
potent in vitro and acute in vivo actions. Mice (n = 8) fed standard rodent diet and injected
with saline were used as lean controls. Energy intake, bodyweight, non-fasting blood glucose
and plasma insulin concentrations were monitored every 72 h throughout the duration of the
study. At the end of the 28 day treatment period, glucose tolerance (18 mmol/kg body weight,
intraperitoneal or oral, overnight fasted) and insulin sensitivity (25 U/kg body weight) were
assessed as previously described [12–14]. Indirect calorimetry and energy expenditure in
treated and control mice were measured using the Comprehensive Laboratory Animal Moni-
toring System (CLAMS) metabolic chambers (Columbus Instruments, Columbus, OH, USA).
Total body lean and fat mass, bone mineral density and bone mineral content were also mea-
sured using DXA scanning (Piximus Densitometer, USA) [21]. Improvement in beta cell func-
tion in [L28K]esculentin-2CHa-treated and control mice were evaluated from the insulin
secretory responses of islets isolated from these animals to established insulin secretagogues
and incretin hormones (16.7 mM glucose, 1 μMGLP-1, 1 μMGIP, 10 mM alanine, 10 mM
arginine and 30 mM KCl). Changes in islet morphology were assessed using pancreatic tissues
excised from mice treated with [L28K]esculentin-2CHa or saline for 28 days as previously
described [12–14].
Biochemical measurements
Pancreatic tissues were homogenized in 20 mM Tris-HCl, 150 mMNaCl, 1 mM EDTA, 1 mM
EGTA and 0.5% Triton X 100; pH 7.5 as previously described [14]. Blood samples (approxi-
mately 150 μl), collected from the cut tip of the tail vein of unanesthetized mice at intervals
indicated in the Figures were used for blood glucose measurements and determination of
plasma insulin as previously described [13,14]. Blood glucose was measured using a hand-held
Ascencia Contour meter (Bayer Healthcare, UK). Plasma and pancreatic insulin were deter-
mined by radioimmunoassay [20]. Plasma and pancreatic glucagon contents were determined
by ELISA using commercially available kit (Millipore, MA, USA). Plasma creatinine, alanine
transaminase (ALT), aspartic acid transaminase (AST) and alkaline phosphatase (ALP) were
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measured using commercially available kits (Randox Laboratories, UK) as indicators of renal
and liver function. Plasma triglyceride and cholesterol concentrations were measured using an
automated clinical chemistry analyser (I-lab 650, and reagents purchased from Instrumenta-
tion Laboratory (Warrington, UK). The assay kit for cholesterol was obtained from Randox
Laboratories (Antrim, UK). Estimation of LDL cholesterol concentrations was achieved using
the Friedewald equation as described previously [22].
Statistical analysis
Results are expressed as mean ± S.E.M. Values were compared using one-way ANOVA
followed by Student-Newman-Keuls post hoc test. Area under the curve (AUC) analysis was
performed using the trapezoidal rule with baseline correction. P< 0.05 was considered statisti-
cally significant.
Results
In vitro insulin releasing effects
The basal rate of insulin secretion from BRIN BD11 cells at 5.6 mM glucose was about 5% of
total insulin content of one million cells in 20 min. This was increased by 7.3-fold in the pres-
ence of alanine (10mM) (P<0.001; n = 8) (Fig 1A). Esculentin-2CHa produced a significant
(P< 0.05) and concentration-dependent stimulation of insulin release at
concentrations 0.03nM. At the highest concentration of 3μM, the peptide produced a near
maximum 10.3-fold insulin-secretory response (P< 0.001). All analogues of esculentin-2CHa
tested produced a significant (P< 0.05) and concentration-dependent stimulation of insulin
release from BRIN-BD11 cells (Fig 1B). The threshold concentration (minimum concentration
producing a significant increase in the rate of insulin release) of all analogues, except [D20K,
D27K]esculentin-2CHa, was 0.01 nM. Stimulatory effects at 3 μM of [L28K]- and [C31S]-escu-
lentin-2CHa were significantly (P< 0.05) greater than those of the native peptide and the
other analogues (Table 2).
The insulinotropic actions of esculentin-2CHa and its analogues were replicated in incuba-
tions performed with isolated mouse islets (Fig 1C and 1D). Basal insulin release from islets
at 16.7 mM glucose was increased 2.4-fold by GLP-1 (10−6 M). A similar threshold concentra-
tion was observed for esculentin-2CHa and its [L21K], [L24K] and [D20K, D27K] analogues at
16.7 mM glucose (Table 2). However, other analogues stimulated insulin secretion from islets
at concentrations 1 nM. The stimulation produced by the highest concentration of esculen-
tin-2CHa (1 μM, 2.7-fold, P< 0.001) was comparable to the insulinotropic effect exhibited by
the same concentration (1 μM) of its [L21K] (2.6-fold, P< 0.001), [C31S, C37S] (2.6-fold,
P< 0.001) and [D20K,D27K] analogues (1.7-fold, P< 0.001) but was significantly (P< 0.05)
higher that the effect observed for [L24K]-esculentin-2CHa (1 μM, 2.3-fold) under the same
experimental conditions. The stimulatory effects of the [L28K] (1 μM, 3.4-fold, P< 0.001) and
[L31K] (1 μM, 3.3-fold, P< 0.001) analogues on isolated islets were significantly higher when
compared with the native peptide (Table 2).
The stimulatory effects of esculentin-2CHa (1 μM) and its substituted analogues on
BRIN-BD11 cells increased progressively as the concentration of glucose in the incubation
buffer was increased from 1.1 to 16.7mM (Fig 1E). However, the stimulatory action of esculen-
tin-2CHa (Fig 1F) and its analogues were significantly inhibited by diazoxide (300 μM, 52–
57%, P< 0.001), verapamil (50 μM, 31–35%, P< 0.001) and by the absence of extracellular
calcium (49–55%, P<0.001). No significant release of lactate dehydrogenase (LDH) from
BRIN-BD11 cells was observed following incubation with esculentin-2CHa or any analogue
tested (Fig 1G).
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Effects on membrane potential and intracellular Ca2+ concentration
Membrane potential of BRIN BD11 cells was increased by 5.2-fold (P< 0.001) in the presence
of KCl (30 mM, Fig 2A and 2B). Esculentin-2CHa (1 μM) and its analogues also depolarized
BRIN-BD11 cells, producing a 2.1-fold (P< 0.001) increase of membrane potential compared
with 5.6mM glucose (Table 2). While alanine (10 mM) produced a marked increase (4.6-fold,
P< 0.001) in the concentration of intracellular Ca2+, esculentin-2CHa and its analogues elic-
ited only a modest response (1 μM, 1.5-fold, P< 0.05, Fig 2C and 2D, Table 2).
Fig 1. Dose dependent effects of esculentin-2CHa and its substituted analogues on insulin release
from BRIN-BD11 cells (A, B, E, F) andmouse islets (C, D). Effects on lactate dehydrogenase (LDH)
release (G) is also shown. Values are mean ± SEMwith n = 8. For A, B, D and F, *P < 0.05, **P < 0.01,
***P < 0.001 compared with 5.6mM glucose. For B and D, ΔP < 0.05, ΔΔP < 0.01 compared with native
esculentin-2CHa. For C, *P < 0.05, **P < 0.01, ***P < 0.001 compared with 16.7 mM glucose. For E,
*P < 0.05, **P < 0.01, ***P < 0.001 compared with the same concentration of glucose alone. ΔP<0.05
compared with esculentin-2CHa at the same glucose concentration. ++P < 0.01, +++P < 0.001 compared with
incubation at 5.6 mM glucose for each peptide. For F, ΔΔΔP < 0.001 compared with respective incubation in
the absence of the peptide. +P < 0.05, ++P < 0.01, +++P < 0.001 compared with incubation at 5.6 mM glucose
in the presence of esculentin-2CHa alone.
doi:10.1371/journal.pone.0141549.g001
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Acute in vivo effects on glucose tolerance and insulin release
Acute in vivo effects of esculentin-2CHa and its analogues were assessed in high fat mice with
obesity-diabetes. Intraperitoneal administration of esculentin-2CHa (75 nmol/kg body weight)
with glucose (18 mmol/kg body weight) significantly decreased the plasma glucose excursion
compared with injection of glucose alone (Fig 3A). Integrated responses, presented as area
under the glucose curve, showed that plasma glucose was 33% (P< 0.05) lower in mice injected
with esculentin-2CHa (Fig 3B). This was accompanied by a 48% (P< 0.01, Fig 3C and 3D)
increase in the integrated insulin response. The plasma glucose response was reduced by
4–52% (P 0.05) using different analogues of esculentin-2CHa, with the [L28K] and [C31K]
peptides producing 52% (P< 0.01) and 40% (P< 0.05) decreases respectively (Table 3). A sim-
ilar trend was observed for acute effects of the analogues on insulin secretion in high fat fed
mice. Plasma insulin response was increased by 10–134% in mice treated with the [L28K] and
[C31K] analogues producing stimulating responses that were 2.8- and 2.4-fold greater than
that observed with esculentin-2CHa (Table 3).
Effects of 28 day administration of [L28K]esculentin-2CHa on body
weight, food intake and non-fasting plasma glucose and insulin
concentrations
Based on its superior in vitro and acute in vivo effects, [L28K]esculentin-2CHa was selected for
longer-term studies using high fat fed mice. These animals exhibited increased body weight,
food intake, plasma glucose and insulin concentrations compared with control animals fed a
standard diet (Fig 4). Treatment with [L28K]esculentin-2CHa for 28 days did not affect body
weight or food intake but resulted in 25% (P< 0.05, Fig 4C) reduction in non-fasting plasma
glucose and a 42% (P< 0.05, Fig 4D) increase in non-fasting plasma insulin compared with
saline-treated controls.
Table 2. Effects of esculentin-2CHa and its analogues on insulin- and LDH-release, membrane potential and intracellular calcium concentration in
BRIN-BD11 cells.
Peptide BRIN-BD11 cells
(Threshold concentration)
Mouse islets (Threshold
concentration)
LDH release (%
of control)
Membrane potential
(AUC, x 103 RFU)
Intracellular Ca2+
(AUC, x 102 RFU)
Control (Glucose
5.6mM)
- - 100.0±2.9 3.71±1.05 4.30±0.40
Esculentin-2CHa 0.3nM 10nM 102.7±1.1 8.01±0.28** 6.44±0.47*
[L21K]Esculentin-
2CHa
0.01nM 10nM 100.6±2.0 7.78±0.31** 6.14±0.41*
[L24K]Esculentin-
2CHa
0.01nM 10nM 101.3±3.1 7.87±0.19** 6.28±0.62*
[L28K]Esculentin-
2CHa
0.01nM 1nM 101.8±1.5 7.78±0.22** 7.28±0.94*
[C31K]Esculentin-
2CHa
0.01nM 0.1nM 100.2±2.8 7.92±0.14** 6.32±0.72*
[C31S, C37S]
Esculentin-2CHa
0.01nM 1nM 104.3±3.1 7.96±0.24** 6.55±0.36*
[D20K, D27K]
Esculentin-2CHa
0.1nM 10nM 102.5±2.6 7.85±0.32** 6.10±0.46*
LDH release data were obtained at the highest peptide concentration (3 μM). Membrane potential and intracellular Ca2+ experiments were carried out at
1μM concentration. Values are mean ± SEM with n = 8.
*P < 0.05
**P < 0.01 compared with 5.6mM glucose.
doi:10.1371/journal.pone.0141549.t002
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Effects of 28 day administration of [Lys28]esculentin-2CHa on glucose
tolerance and insulin-sensitivity
Treatment of high fat fed mice with [L28K]esculentin-2CHa resulted in significant improve-
ment of intraperitoneal glucose tolerance and glucose-stimulated insulin secretion (P< 0.05,
Fig 5A–5D). Area under the curve values (AUC 0–60 min) for glucose and insulin concentra-
tions showed an improvement of 20% (P< 0.05, Fig 5B) and 66% (P< 0.01, Fig 5D) respec-
tively. Similarly, the glycaemic excursion following oral glucose (23%, P< 0.01, Fig 5E and 5F)
and the accompanying insulin response (68%, P< 0.001, Fig 5G and 5H) were also improved
in mice treated with [L28K]esculentin-2CHa. Treatment with the peptide had no significant
effect on insulin sensitivity in high fat fed mice (Fig 5I and 5J).
Effects of 28 day administration of [L28K]esculentin-2CHa on indirect
calorimetry, energy expenditure and body composition in high fat fed
mice
Oxygen (O2) consumption, CO2 production and energy expenditure in high fat fed mice
increased by 30% (P< 0.001), 22% (P< 0.001) and 27% (P< 0.001) respectively but these
parameters together with respiratory exchange ratio were not affected by treatment with
[L28K]esculentin-2CHa (S1 Fig). Treatment with [L28K]esculentin-2CHa reversed the loss in
bone area but did not affect body fat content and lean body mass in high fat fed mice (S2 Fig).
However, saline-treated high fat fed mice exhibited significantly (P< 0.001) reduced bone area
(13%, P< 0.001) and increased body fat (2.0-fold, P< 0.001) (S2 Fig) Bone mineral density
and bone mineral content were similar in all groups of mice (S2 Fig).
Fig 2. Effects of esculentin-2CHa onmembrane potential (A, B) and intracellular calcium
concentration (C, D) in BRIN-BD11 cells expressed as relative fluorescence unit, RFU (A, C) and area
under the curve, AUC (B, D). Cells were incubated with esculentin-2CHa (1 μM) or its substituted analogue
and data were collected every 1.52 s over a period of 5 min. Values are mean ± SEMwith n = 6. *P < 0.05,
**P < 0.01, ***P < 0.001 compared with 5.6 mM glucose.
doi:10.1371/journal.pone.0141549.g002
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Effects of 28 day administration of [L28K]esculentin-2CHa on pancreatic
weight, insulin content and islets insulin secretory responses of isolated
islets
Pancreatic weights were similar in all groups of mice (Fig 6A). However, the greater total pan-
creatic insulin content of high fat fed mice was reversed by treatment with [L28K]esculentin-
2CHa (Fig 6B). Compared with lean control mice, secretory responses of islets isolated from
high fat fed mice were significantly decreased to 1.4 (27%, P< 0.05), 5.6 (42%, P< 0.05) or
16.7 mM glucose (43%, P< 0.01), GLP-1 (1 μM, 42%, P< 0.05), GIP (1 μM, 40%, P< 0.05),
alanine (10 mM, 45%, P< 0.05), arginine (10 mM, 41%, P< 0.05) and KCl (30 mM, 33%,
P< 0.05). However, treatment with [L28K]esculentin-2CHa for 28 days restored the insulin-
secretory responses to each of these secretagogues (Fig 6C and 6D).
Effects of 28 day administration of [L28K]esculentin-2CHa on pancreatic
and plasma glucagon content, lipid profile and both renal and liver
function
The elevated pancreatic and plasma glucagon levels generated by high fat feeding were reduced
by 20% (P< 0.05) and 35% (P< 0.05) in [L28K]esculentin-2CHa-treated mice (Fig 7A and 7B).
Plasma total cholesterol were similar in all groups while high fat fed mice exhibited reduced
plasma HDL cholesterol (23%, P< 0.05) and elevated plasma triglycerides (1.2-fold, P< 0.05)
(Fig 7C). Treatment with [L28K]esculentin-2CHa for 28 days had no effect on HDL cholesterol
but significantly (P< 0.05) decreased plasma triglycerides. Plasma levels of AST and ALT were
similar in all groups of mice, plasma ALP was decreased (43%, P< 0.01) and creatinine increased
(140%, P< 0.001) in high fat fed mice compared with lean controls (Fig 7D and 7E).
Fig 3. Effects of esculentin-2CHa on glucose tolerance (A, B) and plasma insulin response to glucose
(C, D) in high fat fed mice expressed as line graph (A, C) and area under the curve, AUC (B, D). Values
are mean ± SEMwith n = 8. *P < 0.05 compared with control
doi:10.1371/journal.pone.0141549.g003
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Administration of [L28K]esculentin-2CHa for 28 days resulted in 43% (P< 0.05, Fig 7D)
increase in plasma ALP and 40% (P< 0.05, Fig 7E) decrease in plasma creatinine levels.
Effects of 28 day administration of [L28K]esculentin-2CHa on islet
morphology, beta cell and alpha cell area
Islets isolated from saline-treated high fat fed mice were significantly larger than those isolated
from lean mice (Fig 8A). The number of islets per mm2 of pancreas as well as beta and alpha
cells area were also significantly (P 0.05) increased in high fat fed mice (Fig 8B–8E). Treat-
ment with [L28K]esculentin-2CHa did not affect the number of islets per mm2 of pancreas but
significantly reduced total islet area (44%, P<0.001) as well as beta (43%, P< 0.001) and alpha
(48%, P< 0.001) cell areas.
Discussion
The increasing incidence of type 2 diabetes together with ever mounting challenges posed by
associated complications have motivated efforts to discover novel antidiabetic agents with bet-
ter therapeutic outcomes [23]. The present study provides further evidence for the potentially
beneficial actions of the esculentin-2CHa family of peptides and highlights their possible utility
in the management of type 2 diabetes. Consistent with observations using several other
amphibian host defence peptides [10], esculentin-2CHa stimulates insulin release from
BRIN-BD11 cells in a dose-dependent and glucose-responsive manner at concentrations that
are non-toxic to the cells. However, magnitude of the effects of the peptide, particularly at the
highest concentration tested (3 μM), were appreciably greater than those previously reported
for other amphibian host-defence peptides [9]. Indeed, the stimulatory effect of esculetin-
2CHa on isolated mouse islets is comparable in magnitude to that of GLP-1 under the same
experimental conditions [24,25]. Membrane depolarization and enhanced intracellular Ca2+
concentrations together with the reduced insulin release in the presence of diazoxide,
Table 3. Acute effects of esculentin-2CHa and its analogues on glucose tolerance and insulin release
in high fat fed mice.
Peptide Plasma glucose (AUC, mmol/l.
min)
Plasma insulin (AUC, ng/ml.
min)
Control 693.53±71.34 111.86±14.03
Esculentin-2CHa 463.99±46.95* 165.05±16.89*
[L21K]Esculentin-2CHa 598.68±35.23ΔΔ 131.12±14.25Δ
[L24K]Esculentin-2CHa 662.25±32.14ΔΔ 129.89±11.02Δ
[L28K]Esculentin-2CHa 327.61±36.87**, Δ 262.81±30.56**,ΔΔΔ
[L31K]Esculentin-2CHa 410.72±29.25* 240.32±31.04**,ΔΔΔ
[C31S, C37S]Esculentin-
2CHa
618.65±86.0ΔΔ 122.74±28.65Δ
[D20K, D27K]Esculentin-
2CHa
667.78±60.23ΔΔ 122.96±16.76Δ
Plasma glucose and insulin were measured prior to and after intraperitoneal administration of high fat fed
mice with glucose (18 mmol/kg) alone (control) or in combination with peptide (75 nmol/kg body weight).
Integrated responses to are presented as area under the curve values (AUC) for data collected at 0, 15, 30
and 60 min after peptide administration. Values are mean ± SEM with n = 8.
*P < 0.05
**P < 0.01 compared with control 5.6mM glucose. ΔP < 0.05, ΔΔP<0.01, ΔΔΔP<0.001 compared with mice
injected with esculentin-2CHa.
doi:10.1371/journal.pone.0141549.t003
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verapamil or Ca2+ chelation suggest that the insulinotropic action of esculentin-2CHa, in com-
mon with other but not all previously identified insulinotropic amphibian skin peptides [5,10],
may involve the activation of the KATP-dependent pathway of insulin secretion [26]. This is
fully supported by initial patch clam experiments evaluating effects of [Arg4]tigerinin-1R in
clonal BRIN-BD11 beta cells (R. C. Moffett et al., unpublished observations). This analogue
derived from tigerinin-1R isolated from the skin secretions ofHoplobatrachus rugulosus has
similar action prolife to esculentin-2CHa. However, effects on other elements of beta cell signal
transduction pathways such as glucose metabolism (glycolysis or mitochondrial metabolism),
intracellular cyclic AMP generation or activation of phospholipase C should not be ruled out.
Indeed, insulin secretion was largely preserved in the presence of diazoxide or verapamil, as
well as under Ca2+ free conditions, indicating that almost half of the insulin secretory response
induced by esculentin-2CHa is dependent neither on KATP channel closure nor L-type Ca
2+
channel activation.
We have demonstrated previously in studies using the amphibian peptides pseudin-2 [15],
B2RP [27], alyteserin-2a [28] and tigerinin-1R [29] that site-specific amino acid substitutions
that result in increasing cationicity may lead to significant enhancement of their in vitro insulin
releasing actions. In this study, such amino acid substitutions resulted in increased net charge
and isoelectric point (Table 1) as well as enhanced insulinotropic potency. However, the
responses to a 3μM stimulus of all analogues of esculentin-2CHa tested, except the [L28K] and
[C31K] peptides, were lower compared with the native peptide.
Fig 4. Effects of [L28K]esculentin-2CHa on body weight (A), cumulative energy intake (B), non-fasting
plasma glucose (C) and insulin (D) in lean and high-fat fed mice. Parameters were measured 3 days
prior to, and every 72 hours during twice-daily treatment (indicated by the black bar) with saline or
[L28K]esculentin-2CHa (75 nmol/kg bodyweight) for 28 days. Values are mean ± SEMwith n = 8 mice.
*P < 0.05, *** P < 0.001 compared to high fat fed control. All parameters were significantly lower in lean mice
than high fat fed control mice (P < 0.05 –P < 0.001).
doi:10.1371/journal.pone.0141549.g004
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Consistent with previous studies [11], mice fed a high fat diet exhibited glucose intolerance
and insulin resistance. Acute injection with esculentin-2CHa significantly improved both oral
and intraperitoneal glucose tolerance and increased insulin secretion. These in vivo actions
were greater with the [D28K] and [C31S] analogues while the in vitro insulinotropic actions of
the other peptide analogues were not replicated in vivo. The in vivo effects of [L28K] and
[C31K]esculentin-2CHa in these animals were more pronounced than those previously
reported for other amphibian skin peptides [12–14,30]. Twice-daily administration of [L28K]
esculentin-2CHa for 28 days did not affect body weight and food intake but reduced hypergly-
caemia and elevated plasma insulin concentrations in the non-fasting state. This was associated
with improved glucose tolerance following oral and intraperitoneal glucose administration
accompanied by enhanced insulin secretion. These observations are broadly consistent with
effects of tigerinin-1R [12], [I10W]-tigerinin-1R [30] and magainin-AM2 [13], suggesting a
possible similar spectrum of actions in this animal model of obesity and diabetes. We have pre-
viously shown that the antidiabetic effects of magainin-AM2 [13] and [I10W]-tigerinin-1R
[30] were accompanied by improvement in insulin sensitivity. However, in the present study,
the insulin resistance induced by high fat feeding was not alleviated in mice treated with
[L28K]esculentin-2CHa. It is probable, therefore, that the improvement of glucose homeostasis
observed in this study is largely due the effects of the peptide on islet cell function. Consistent
with this view, the reduced insulin-secretory responses to incretin hormones and other insulin
secretagogues observed with islets isolated from saline treated high fat fed mice were reversed
by treatment with [L28K]esculentin-2CHa.
Fig 5. Effects of [L28K]esculentin-2CHa on plasma glucose and insulin concentrations following intraperitoneal (A–D) and oral (E-H) glucose
administration (18 mmol/kg body weight) in lean and high-fat fed mice as well as insulin sensitivity (I, J). Insulin sensitivity tests were performed using
25 U/kg body weight of insulin injected intraperitoneally. All tests were conducted following twice-daily treatment of mice with saline or [L28K]esculentin-
2CHa (75 nmol/kg body weight) for 28 days. Values are mean ± SEM with n = 8 mice. *P < 0.05, **P < 0.01 and ***P < 0.001 compared with saline-treated
lean mice. ΔP < 0.05, ΔΔP < 0.01 compared with high-fat fed control.
doi:10.1371/journal.pone.0141549.g005
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Fig 6. Effects of [L28K]esculentin-2CHa on (A) pancreatic weight, (B) pancreatic insulin content and
(C) insulin-secretory responses of islets isolated from lean and high-fat fed mice treated with saline or
[L28K]esculentin-2CHa (75 nmol/kg body weight) for 28 days. Values are means ± SEM for 8 mice. For
Fig 6B, ***P < 0.001 compared with lean control, ΔP < 0.01 compared with high-fat control. For Fig 6C,
*P < 0.05,**P < 0.01, ***P < 0.001 compared with the response of islets isolated from the same group of
mice at 16.7 mM glucose; ΔP < 0.05, ΔΔP < 0.01, ΔΔΔP < 0.001 compared with the respective response of
islets isolated from lean control. For Fig 6D, stimulation index refers to fold-increase in insulin secretion from
1.4 mM glucose to 16.7 mM glucose or from 16.7 mM glucose to that observed in the presence of each
secretagogue. *P < 0.05, **P < 0.01 compared with the stimulation index of islets isolated from each group
of mice at 16.7mM glucose. ΔP < 0.05, ΔΔP < 0.01 compared the stimulation index of lean control.
doi:10.1371/journal.pone.0141549.g006
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Unrestrained hepatic glucose output and elevated glucagon secretion make an important
contribution to the development of hyperglycaemia in type 2 diabetes [31]. Interesting, the ele-
vation of pancreatic and plasma glucagon concentrations as well as α-cell area in saline-treated
high fat fed mice were normalized by treatment with [L28K]esculentin-2CHa. Although the
exact molecular mechanism through which the peptide inhibits α-cell function is not yet
known, our results suggest that such effects contribute to the improvement of hyperglycaemia
and glucose tolerance. Thus, further studies are required to assess whether [L28K]esculentin-
2CHa acts directly on β cells or by indirect effects mediated via enteroendocrine secretions
such as GLP-1. Increased islet size accompanying enhanced insulin output and defective β-cell
function caused by high fat feeding were also reversed in [L28K]esculentin-2CHa-treated mice.
Our preliminary work with analogues of the parent peptide indicate that this may be due to
correction of the ratio of beta cell proliferation to apoptosis.
Energy metabolism was not affected by treatment with [L28K]esculentin-2CHa. Similarly,
the peptide did not affect adipose tissue deposition, bone mineral content or bone mineral den-
sity in high fat fed mice. Bone area and lean body mass were increased in [L28K]esculentin-
Fig 7. Effects of [L28K]esculentin-2CHa on plasma glucagon content (A), pancreatic glucagon
content (B), plasma lipid profile (C), plasma concentrations of AST, ALT and ALP (D) and plasma level
of creatinine (E) in lean and high-fat fed mice.Mice were treated with twice-daily injections of saline or
[L28K]esculentin-2CHa (75 nmol/kg body weight) for 28 days prior to measurement of biochemical
parameters. Values are mean ± SEMwith n = 8. *P < 0.05, **P < 0.01, ***P < 0.01 compared with lean
control. ΔP < 0.05 compared with high-fat control.
doi:10.1371/journal.pone.0141549.g007
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2CHa-treated mice, but this did not translate to changes in overall body weight. Further studies
are required to evaluate long-term impact of [L28K]esculentin-2Cha on circulating cytokines
and insulin signalling pathways. Importantly, no adverse effects were observed in mice treated
with the peptide, including unchanged circulating concentrations of AST, ALT and ALP
together with improved creatinine clearance and lower circulating triglycerides. Although lon-
ger term toxicological studies are obviously needed, these observations suggest both benefits
and lack of toxicity of [L28K]esculentin-2CHa.
Conclusions
In conclusion, this study has demonstrated the beneficial effects of esculentin-2CHa family
of peptides in mice with diet-induced obesity-diabetes. [L28K]esculentin-2CHa exhibited
better in vitro insulinotropic potential compared with the native peptide and significantly
improved glucose tolerance and enhanced insulin secretion by positive effects on beta cell
function in high fat fed mice. These observations together with the previous demonstrated
antimicrobial actions [8] encourage further evaluation of the potential of [L28K]esculen-
tin-2CHa as a novel agent for managing patients with type 2 diabetes and associated micro-
bial infections.
Fig 8. Effects of [L28K]esculentin-2CHa on islet morphology (A) and computed islet number (B), islet
area (C), beta cell area (D) and alpha cell area (E) in lean and high-fat fed mice.Mice were treated with
twice-daily injections of saline or [L28K]esculentin-2CHa (75 nmol/kg body weight) for 28 days prior to
excision of pancreatic tissue for immunohistological analysis. Values are mean ± SEM for 8 observations
(~120 islets per group). *P < 0.05, **P < 0.01, ***P < 0.001 compared to lean control. ΔΔΔP < 0.001
compared to high fat control.
doi:10.1371/journal.pone.0141549.g008
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Supporting Information
S1 Fig. Effects of [L28K]esculentin-2CHa on O2 consumption (A, B), CO2 production (C,
D), respiratory exchange ratio (E, F) and energy expenditure (G, H) in lean and high-fat
fed treated with saline or [L28K]esculentin-2CHa (75nmol/kg bw) for 28 days.Mice were
placed in CLAMS metabolic chambers, and O2 consumption or CO2 production were mea-
sured for 30s at 15min intervals. RER was calculated by dividing VCO2 by VO2. Energy expen-
diture was computed using the formula (3.815 + 1.232 x RER) x VO2. Values are means ± SEM
for 6 mice. P<0.01, P<0.001 compared with saline-treated lean mice. Shaded bar indi-
cates dark phase.
(TIF)
S2 Fig. Effects of [L28K]esculentin-2CHa on body composition in normal or high-fat fed
mice.Mice were treated with twice-daily injections of saline or [Lys28]esculentin-2CHa
(75nmol/kg body weight) for 28 days prior to DEXA scan (A) and computation of data on lean
body mass (B), body fat (C, D), bone mineral density (E), bone mineral content (F) and bone
area (G). Values are means ± SEM for 8 mice. P<0.05, P<0.01, P<0.001compared with
lean control. ΔΔΔP<0.01 compared with high fat control.
(TIF)
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